Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Med Decis Making ; 43(1): 53-67, 2023 Jan.
Article in English | MEDLINE | ID: mdl-35997006

ABSTRACT

BACKGROUND: Network meta-analysis (NMA) and indirect comparisons combine aggregate data (AgD) from multiple studies on treatments of interest but may give biased estimates if study populations differ. Population adjustment methods such as multilevel network meta-regression (ML-NMR) aim to reduce bias by adjusting for differences in study populations using individual patient data (IPD) from 1 or more studies under the conditional constancy assumption. A shared effect modifier assumption may also be necessary for identifiability. This article aims to demonstrate how the assumptions made by ML-NMR can be assessed in practice to obtain reliable treatment effect estimates in a target population. METHODS: We apply ML-NMR to a network of evidence on treatments for plaque psoriasis with a mix of IPD and AgD trials reporting ordered categorical outcomes. Relative treatment effects are estimated for each trial population and for 3 external target populations represented by a registry and 2 cohort studies. We examine residual heterogeneity and inconsistency and relax the shared effect modifier assumption for each covariate in turn. RESULTS: Estimated population-average treatment effects were similar across study populations, as differences in the distributions of effect modifiers were small. Better fit was achieved with ML-NMR than with NMA, and uncertainty was reduced by explaining within- and between-study variation. We found little evidence that the conditional constancy or shared effect modifier assumptions were invalid. CONCLUSIONS: ML-NMR extends the NMA framework and addresses issues with previous population adjustment approaches. It coherently synthesizes evidence from IPD and AgD studies in networks of any size while avoiding aggregation bias and noncollapsibility bias, allows for key assumptions to be assessed or relaxed, and can produce estimates relevant to a target population for decision-making. HIGHLIGHTS: Multilevel network meta-regression (ML-NMR) extends the network meta-analysis framework to synthesize evidence from networks of studies providing individual patient data or aggregate data while adjusting for differences in effect modifiers between studies (population adjustment). We apply ML-NMR to a network of treatments for plaque psoriasis with ordered categorical outcomes.We demonstrate for the first time how ML-NMR allows key assumptions to be assessed. We check for violations of conditional constancy of relative effects (such as unobserved effect modifiers) through residual heterogeneity and inconsistency and the shared effect modifier assumption by relaxing this for each covariate in turn.Crucially for decision making, population-adjusted treatment effects can be produced in any relevant target population. We produce population-average estimates for 3 external target populations, represented by the PsoBest registry and the PROSPECT and Chiricozzi 2019 cohort studies.


Subject(s)
Network Meta-Analysis , Humans , Bias
2.
Biomed Res Int ; 2018: 3293584, 2018.
Article in English | MEDLINE | ID: mdl-29511676

ABSTRACT

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by remodeling of the pulmonary vasculature and a rise in right ventricular (RV) afterload. The increased RV afterload leads to right ventricular failure (RVF) which is the reason for the high morbidity and mortality in PAH patients. The objective was to evaluate the therapeutic efficacy and antiremodeling potential of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil and the soluble guanylate cyclase stimulator riociguat in a model of pressure overload RV hypertrophy induced by pulmonary artery banding (PAB). Mice subjected to PAB, one week after surgery, were treated with either sildenafil (100 mg/kg/d, n = 5), riociguat (30 mg/kg/d, n = 5), or vehicle (n = 5) for 14 days. RV function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometry. Both sildenafil and riociguat prevented the deterioration of RV function, as determined by a decrease in RV dilation and restoration of the RV ejection fraction (EF). Although both compounds did not decrease right heart mass and cellular hypertrophy, riociguat prevented RV fibrosis induced by PAB. Both compounds diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro. Treatment with either riociguat or sildenafil prevented the progression of pressure overload-induced RVF, representing a novel therapeutic approach.


Subject(s)
Heart Failure/drug therapy , Hypertension, Pulmonary/drug therapy , Pyrazoles/administration & dosage , Pyrimidines/administration & dosage , Sildenafil Citrate/administration & dosage , Ventricular Dysfunction, Right/drug therapy , Animals , Cyclic Nucleotide Phosphodiesterases, Type 5/genetics , Disease Models, Animal , Heart/drug effects , Heart/physiopathology , Heart Failure/genetics , Heart Failure/pathology , Heart Ventricles/drug effects , Heart Ventricles/physiopathology , Humans , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/pathology , Male , Mice , Phosphodiesterase 5 Inhibitors/administration & dosage , Pressure , Pulmonary Artery/drug effects , Pulmonary Artery/physiopathology , Vascular Remodeling/drug effects , Ventricular Dysfunction, Right/genetics , Ventricular Dysfunction, Right/pathology
4.
Physiol Rep ; 5(6)2017 Mar.
Article in English | MEDLINE | ID: mdl-28330950

ABSTRACT

Right ventricular (RV) remodeling represents a complex set of functional and structural adaptations in response to chronic pressure or volume overload due to various inborn defects or acquired diseases and is an important determinant of patient outcome. However, the underlying molecular mechanisms remain elusive. We investigated the time course of structural and functional changes in the RV in the murine model of pressure overload-induced RV hypertrophy in C57Bl/6J mice. Using magnetic resonance imaging, we assessed the changes of RV structure and function at different time points for a period of 21 days. Pressure overload led to significant dilatation, cellular and chamber hypertrophy, myocardial fibrosis, and functional impairment of the RV Progressive remodeling of the RV after pulmonary artery banding (PAB) in mice was associated with upregulation of myocardial gene markers of hypertrophy and fibrosis. Furthermore, remodeling of the RV was associated with accumulation and activation of mast cells in the RV tissue of PAB mice. Our data suggest possible involvement of mast cells in the RV remodeling process in response to pressure overload. Mast cells may thus represent an interesting target for the development of new therapeutic approaches directed specifically at the RV.


Subject(s)
Heart Ventricles/metabolism , Hypertension, Pulmonary/metabolism , Hypertrophy, Right Ventricular/metabolism , Mast Cells/metabolism , Ventricular Remodeling/physiology , Animals , Disease Models, Animal , Heart Ventricles/diagnostic imaging , Hypertension, Pulmonary/diagnostic imaging , Hypertrophy, Right Ventricular/diagnostic imaging , Magnetic Resonance Imaging , Male , Mice , Mice, Inbred C57BL , Ventricular Pressure/physiology
5.
Biomed Res Int ; 2015: 438403, 2015.
Article in English | MEDLINE | ID: mdl-25667920

ABSTRACT

OBJECTIVE: The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood. The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice. METHODS: Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day). Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods. Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues. RESULTS: Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro. CONCLUSION: 5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis. Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice. Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.


Subject(s)
Heart Failure/metabolism , Heart/drug effects , Protective Agents/pharmacology , Receptor, Serotonin, 5-HT2B/metabolism , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Ventricular Dysfunction, Right/metabolism , Animals , Endomyocardial Fibrosis/metabolism , Endomyocardial Fibrosis/prevention & control , Hemodynamics/drug effects , Male , Mice , Mice, Inbred C57BL , Myocardium/chemistry , Myocardium/metabolism , Receptor, Serotonin, 5-HT2B/analysis , Receptor, Serotonin, 5-HT2B/genetics
6.
Basic Res Cardiol ; 108(2): 325, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23325387

ABSTRACT

Pulmonary arterial hypertension (PAH) is a fatal disease for which no cure is yet available. The leading cause of death in PAH is right ventricular (RV) failure. Previously, the TNF receptor superfamily member fibroblast growth factor-inducible molecule 14 (Fn14) has been associated with different fibrotic diseases. However, so far there is no study demonstrating a causal role for endogenous Fn14 signaling in RV or LV heart disease. The purpose of this study was to determine whether global ablation of Fn14 prevents RV fibrosis and remodeling improving heart function. Here, we provide evidence for a causative role of Fn14 in pulmonary artery banding (PAB)-induced RV fibrosis and dysfunction in mice. Fn14 expression was increased in the RV after PAB. Mice lacking Fn14 (Fn14(-/-)) displayed substantially reduced RV fibrosis and dysfunction following PAB compared to wild-type littermates. Cell culture experiments demonstrated that activation of Fn14 induces collagen expression via RhoA-dependent nuclear translocation of myocardin-related transcription factor-A (MRTF-A)/MAL. Furthermore, activation of Fn14 in vitro caused fibroblast proliferation and myofibroblast differentiation, which corresponds to suppression of PAB-induced RV fibrosis in Fn14(-/-) mice. Moreover, our findings suggest that Fn14 expression is regulated by endothelin-1 (ET-1) in cardiac fibroblasts. We conclude that Fn14 is an endogenous key regulator in cardiac fibrosis and suggest this receptor as potential new target for therapeutic interventions in heart failure.


Subject(s)
Hypertrophy, Right Ventricular/prevention & control , Myocardium/pathology , Receptors, Tumor Necrosis Factor/physiology , Ventricular Dysfunction, Right/prevention & control , Animals , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Blotting, Western , Cell Differentiation , Cell Proliferation , Collagen/metabolism , Cytokine TWEAK , Endothelin-1/physiology , Familial Primary Pulmonary Hypertension , Fibrosis/prevention & control , Fluorescent Antibody Technique , Hypertension, Pulmonary/complications , Hypertrophy, Right Ventricular/metabolism , Hypertrophy, Right Ventricular/physiopathology , Immunohistochemistry , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mice, Knockout , Myofibroblasts , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Signal Transduction , TWEAK Receptor , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Necrosis Factors/genetics , Tumor Necrosis Factors/metabolism , Up-Regulation , Ventricular Dysfunction, Right/metabolism , Ventricular Dysfunction, Right/physiopathology
7.
J Med Chem ; 55(16): 7054-60, 2012 Aug 23.
Article in English | MEDLINE | ID: mdl-22793499

ABSTRACT

Reprofiling of existing drugs to treat conditions not originally targeted is an attractive means of addressing the problem of a decreasing stream of approved drugs. To determine if 3D shape similarity can be used to rationalize an otherwise serendipitous process, we employed 3D shape-based virtual screening to reprofile existing FDA-approved drugs. The study was conducted in two phases. First, multiple histamine H(1) receptor antagonists were identified to be used as query molecules, and these were compared to a database of approved drugs. Second, the hits were ranked according to 3D similarity and the top drugs evaluated in a cell-based assay. The virtual screening methodology proved highly successful, as 13 of 23 top drugs tested selectively inhibited histamine-induced calcium release with the best being chlorprothixene (IC(50) 1 nM). Finally, we confirmed that the drugs identified using the cell-based assay were all acting at the receptor level by conducting a radioligand-binding assay using rat membrane.


Subject(s)
Databases, Chemical , Histamine H1 Antagonists/chemistry , Models, Molecular , Receptors, Histamine H1/chemistry , Animals , Antidepressive Agents/chemistry , Antidepressive Agents/pharmacology , Brain/metabolism , Calcium/metabolism , Chlorprothixene/chemistry , Chlorprothixene/pharmacology , HeLa Cells , High-Throughput Screening Assays , Histamine/pharmacology , Histamine H1 Antagonists/pharmacology , Humans , Male , Molecular Conformation , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Histamine H1/metabolism , Structure-Activity Relationship , United States , United States Food and Drug Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...